Not Signed In - Biogen Idec Initiates Phase III Clinical Program Of Oral Compound Bg-12 For Multiple Sclerosis
Mon, 15 Jan 2007 08:00 AM EST
... Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS). [click link for full article] ...
Related Topics
- Clinical Trials
- Tysabri
- Interferon Beta-1a Injection (Avonex
- Multiple Sclerosis/ms
- Multiple Sclerosis
- Tuberous Sclerosis
- Myeloma, Multiple
- Multiple Myeloma
- Antithrombin III
- Carbetapentane and Chlorpheniramine
- Myeloma
- Carbetapentane and Chlorpheniramine oral suspension
- Aspirin and Carisoprodol
- Zidovudine Oral Syrup
- Chlorpheniramine and Carbetapentane
- Lichen Sclerosis
- Carbetapentane, Phenylephrine, and Pyrilamine oral suspension
- Multiple Chemical Sensitivity
- Naltrexone
- Pharmacology
email this page
print this page
bookmark this page
feedback on this page
